Thu, 20 Jun 2024 17:00:00 +0900 hourly 1 /release/202406101957 Thu, 20 Jun 2024 17:00:00 +0900 Tokiwa Phytochemical TOKIWA PHYTOCHEMICAL CO., LTD. (hereafter "TOKIWA"), proudly announces its participation in the "Po... TOKIWA PHYTOCHEMICAL CO., LTD.
TOKIWA PHYTOCHEMICAL CO., LTD. (hereafter "TOKIWA"), proudly announces its participation in the "Positive Impact Evaluation" initiative offered by Chiba Bank to enhance its efforts for sustainability management. This initiative entails a comprehensive analysis and assessment of the economic, environmental, and societal impacts -- both positive and negative -- of corporate activities, aimed at providing continuous support for these initiatives. Chiba Bank, in collaboration with Chibagin Research Institute, conducts the evaluation, assisting businesses in setting and tracking key performance indicators (KPIs). To ensure objectivity, the assessment will be reviewed by Japan Credit Rating Agency, Ltd. (JCR), providing third-party opinions (*1).
 
Schematic chart of "Positive Impact Evaluation": https://cdn.kyodonewsprwire.jp/prwfile/release/M106604/202406101957/_prw_PI3fl_UD8Zd3We.png
 
Positive Impact Evaluation product outline: https://cdn.kyodonewsprwire.jp/prwfile/release/M106604/202406101957/_prw_PI2fl_FGTRf8ba.png
 
The framework of this initiative aligns with the "Positive Impact Finance Principles" established by the United Nations Environment Programme Finance Initiative (UNEP FI) (*2). Verification of compliance with these principles has been confirmed through third-party opinions from JCR.
 
Positive Impact Evaluation product outline for TOKIWA PHYTOCHEMICAL: https://cdn.kyodonewsprwire.jp/prwfile/release/M106604/202406101957/_prw_PI4fl_H8iqAcW5.png
 
Established in 1949, TOKIWA is Japan's pioneering phytochemistry company, headquartered in Sakura City, Chiba Prefecture. The company specializes in extracting and refining functional components from plants, producing active pharmaceutical ingredients, health food components, and raw materials for cosmetics, which are supplied to over 2,000 businesses worldwide. TOKIWA also collaborates with universities and research institutions on R&D focused on plant functionality and offers analytical services and contract refining, meeting all phytochemistry-related needs.
 
Celebrating its 75th anniversary in 2024, TOKIWA has issued two private bonds totaling 400 million JPY to support its ESG initiatives. These include raising 100 million JPY through Mizuho Bank's "SDGs Promotion Support Private Bonds" and 300 million JPY through Mitsubishi UFJ Bank's "Empowering the World" private bonds. Guided by its philosophy, TOKIWA aims for 99% carbon neutrality, recycling extraction residues, and promoting educational CSR activities, with the goal of exceeding SDG targets by 2030. The Positive Impact Evaluation, resulting in a 95% funding rate through ESG finance and corporate bonds as of June 2024, underscores TOKIWA's commitment to sustainability management and its vision of becoming the world's leading phytochemistry company by its centenary.
 
Notes:
(*1) For more information on the third-party opinion regarding compliance with the "Principles for Positive Impact Finance" and the rationality of the KPIs used, please visit the Japan Credit Rating Agency's website ( https://www.jcr.co.jp/en/greenfinance/ ).
 
(*2) Organization established based on a voluntary agreement between the United Nations Environment Programme (UNEP), a subsidiary body of the United Nations, and financial institutions
 
For more information, please visit the company's website: https://www.tokiwaph.co.jp/en/
]]> /release/202312204616 Tue, 09 Jan 2024 16:00:00 +0900 Tokiwa Phytochemical TOKIWA PHYTOCHEMICAL CO., LTD. (hereinafter "Tokiwa"), Japan, has announced the publication of the ... TOKIWA PHYTOCHEMICAL CO., LTD.
TOKIWA PHYTOCHEMICAL CO., LTD. (hereinafter "Tokiwa"), Japan, has announced the publication of the latest research on VENETRON (R), extracted from rafuma leaves. The study, titled "Effect of Apocynum venetum Leaf Extract (VENETRON (R)) on Unidentified Complaints Relating to Menstruation in Healthy Female Subjects -- A Randomized, Double-blind, Placebo-controlled Parallel-group Comparison Study --," is featured in the prestigious November 2023 issue of Japanese Pharmacology & Therapeutics (pages 1685-96, No. 11, Vol. 51).
 
Logo: https://cdn.kyodonewsprwire.jp/prwfile/release/M106604/202312204616/_prw_PI1fl_098u359q.jpg
 
This research aimed to assess the efficacy of VENETRON (R) in addressing both psychological and physical complaints associated with menstruation, conducted on healthy women experiencing complaints related to menstruation. The study employed a randomized, double-blind, and placebo-controlled methodology. Evaluation of 8 crucial subscales, including pain, water retention, autonomic reactions, negative effect, concentration, behavioral change, arousal, and control, was carried out using a menstrual distress questionnaire (MDQ) throughout the menstrual cycle.
 
Image1: About VENETRON (R)
https://cdn.kyodonewsprwire.jp/prwfile/release/M106604/202312204616/_prw_PI3lg_l6t5RJVq.jpg
 
The MDQ results demonstrated that VENETRON (R) is effective in alleviating both psychological and physical complaints occurring BEFORE and DURING menstruation. Considering VENETRON (R) is one of Tokiwa’s representative products aimed at sleep quality improvement, it was also evaluated in this research by the Oguri-Shirakawa-Azumi Sleep Inventory for Middle-age and Aged version (OSA-MA). The result indicated that VENETRON (R) improves sleep quality. This outcome suggests that VENETRON (R) could potentially improve sleep quality for a wide range of individuals, including women experiencing menstruation-related discomfort.
 
Image2: Ingestion of VENETRON (R) significantly improves MDQ score before and during menstruation
https://cdn.kyodonewsprwire.jp/prwfile/release/M106604/202312204616/_prw_PI5lg_2MP710eO.jpg
 
These findings underscore the positive impact of VENETRON (R) as a non-hormonal menstrual support ingredient on overall menstrual well-being. Beyond its primary focus, this research contributes to advancing understanding and addressing concerns related to women's health, paving the way for new avenues of research and development in this crucial area.
 
About TOKIWA PHYTOCHEMICAL CO., LTD.
Established in 1949 in Chiba, Japan, Tokiwa made history as the first Japanese company devoted to the intricate field of phytochemistry. Distinguished for its prolific manufacturing of diverse plant extracts and relentless exploration of their therapeutic potential, Tokiwa is now set to embark on an exciting journey of business expansion. With a profound commitment to enhancing human health, the company is poised to make significant contributions to the well-being of individuals worldwide.
 
QR code: https://cdn.kyodonewsprwire.jp/prwfile/release/M106604/202312204616/_prw_PI4lg_ErbwXti3.jpg
 
For more information, please visit: https://www.tokiwaph.co.jp/en/
 
]]> /release/202104193857 Thu, 22 Apr 2021 15:00:00 +0900 Tokiwa Phytochemical Tokiwa Phytochemical Co., Ltd. Announces New Cutting-Edge Study Supporting Benefits of SIRTMAX (R) ... Tokiwa Phytochemical Co., Ltd. Announces New Cutting-Edge Study Supporting Benefits of SIRTMAX (R) on Healthier Life Expectancy
 
Tokiwa Phytochemical Co., Ltd. (hereinafter “Tokiwa”), Japan, is excited to announce the publication of a joint research project with the University of Tokyo on a proprietary extract of “Kaempferia parviflora” (SIRTMAX (R)), commonly known as black turmeric.
 
The study titled “Quercetin 3,5,7,3′,4′-pentamethyl ether from ‘Kaempferia parviflora’ directly and effectively activates human SIRT1” was published in “Communications Biology” magazine. The study led by Tokiwa and Professor Koji Nagata reveals that quercetin 3,5,7,3′,4′-pentamethyl ether (KPMF-8), an active compound of SIRTMAX (R), directly binds with SIRT1 protein and activates SIRT1 far effectively than resveratrol (well-known SIRT activator). KPMF-8 interacts with SIRT1 directly and stimulates SIRT1 activity by enhancing the binding affinity of SIRT1 with its substrate, Ac-p53 peptide. The binding affinity between SIRT1 and Ac-p53 peptide was enhanced 8.2-fold by KPMF-8, but only 1.4-fold by resveratrol. Furthermore, intracellular SIRT1 activity was promoted 1.7-fold by KPMF-8 but only 1.2-fold by resveratrol.
 
Why SIRT1 activation? The “Sirt1 gene,” aka the longevity gene, recharges mitochondria, which tend to wind down with age. In fact, SIRT1 contributes to human longevity by regulating different cell-survival pathways, including delaying replicative senescence, suppressing inflammation and increasing resistance to hypoxic (oxygen-deprived) and heat stress. Considering its vital functions, any substance that can activate SIRT1 is of great interest.
 
KPMF-8 is a component of SIRTMAX (R), which is non-GMO, gluten-free, dairy-free, halal, and kosher ingredient. What’s more, SIRTMAX (R) is 5 times more potent than resveratrol in activating SIRT1. With further validation by this new publication, in addition to its existing evidence, SIRTMAX (R) is poised to be in high demand to support a healthier life expectancy via its promising properties.
 
About Tokiwa Phytochemical Co., Ltd.
Tokiwa was founded in 1949 in Chiba, Japan. Being the first Japanese company to specialize in phytochemistry, the company has been manufacturing numerous plant extracts while tirelessly researching their efficacies. With this exciting news, Tokiwa plans to further expand its business and make contribution to human health. For more information, please visit: https://www.tokiwaph.co.jp/en/
 
 
Source: Tokiwa Phytochemical Co., Ltd.
]]>